Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD)

Sponsor
Heart of England NHS Trust (Other)
Overall Status
Completed
CT.gov ID
NCT02398682
Collaborator
University of Birmingham (Other), University of Warwick (Other)
1,865
1
4
32
58.3

Study Details

Study Description

Brief Summary

The study pilots an outreach service for Acute kidney injury (AKI) patients, based on electronic alerts. Using the alerts we will contact the primary clinician caring for the patient with AKI in the Intervention group. The study has a control group of patients receiving good standard care, but without Outreach. The aim is to reduce morbidity and mortality in the syndrome, and also to reduce healthcare costs.

Condition or Disease Intervention/Treatment Phase
  • Other: Rapid diagnosis of AKI cause
  • Other: Rapid treatment of AKI cause
  • Other: Stopping 'nephrotoxic' drugs
  • Other: Early nephrology followup for stage 3 AKI
  • Other: Preventing recurrent AKI
  • Other: Good standard care
N/A

Detailed Description

Lay summary:

About one in six hospital inpatients suffer Acute Kidney Injury (AKI), also called acute renal failure. About a third of patients with AKI die. The large majority of patients with AKI are managed by doctors who are not kidney experts. Effective AKI advice and treatments are available but not currently integrated into routine care. A recent National review of the care of patients who died from AKI showed poor management of many patients. Early diagnosis of AKI can avoid complications, dialysis (which affects the quality of life of patients, and is costly) or death. AKI is diagnosed by a change in a blood test. We have developed computer software to diagnose AKI earlier. It sends a warning or 'Alert' about the test to our team of kidney experts. We will further develop the settings of the Alert system. It needs to send an Alert for the right patients. We will also study the best way to make clinicians pay attention to their patients who are developing AKI. When our expert Outreach team receive an Alert, they will call the doctor or nurse looking after the patient with AKI. We will advise on the best treatment for that patient, to reduce their risk of death, dialysis and other complications. We will do a pilot study in one large hospital, to further develop the system, and check it reduces the risk of death or complications from AKI. We will use this work to develop a larger trial of this new system of care for patients with AKI in different hospitals. This will convince the wider NHS of the need to change, and show how to prevent or reduce AKI. Ultimately we aim to improve patients' lives by reducing avoidable death and illness from AKI , and also save the NHS money.

Study Design

Study Type:
Interventional
Actual Enrollment :
1865 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) - A Pilot Study to Look at Enhancing Patient Care, Improving Patient Outcomes and Reducing NHS Costs
Study Start Date :
Oct 1, 2014
Actual Primary Completion Date :
May 31, 2017
Actual Study Completion Date :
May 31, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: After study Intervention arm Heartlands

The trial has 4 arms in a Before and After design: Arm 3. After/Heartlands area patients receiving the experimental intervention Patients who have AKI and are either inpatients in the Intervention hospital or living within the surrounding catchment area are eligible. The intervention will be in the form of a telephone call to the primary clinician or visit to the patient. The intervention will include: Rapid diagnosis of AKI cause; Rapid treatment of AKI cause; Stopping 'nephrotoxic' drugs; Early nephrology followup for stage 3 AKI survivors; and preventing recurrent AKI.

Other: Rapid diagnosis of AKI cause
The Outreach team will advise on an evidence-based package of care: 1) Rapidly establish a credible diagnosis of the cause of AKI including: Improved assessment of volume status Standardised use of urine dipstick . Appropriate sepsis investigations. Urgent ultrasound with suspected obstruction.

Other: Rapid treatment of AKI cause
Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.

Other: Stopping 'nephrotoxic' drugs
Cessation of all potentially nephrotoxic drugs.
Other Names:
  • Avoidance of iatrogenic causes of AKI
  • Other: Early nephrology followup for stage 3 AKI
    A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.

    Other: Preventing recurrent AKI
    Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
    Other Names:
  • Patient information to reduce recurrent AKI
  • Other: Good standard care
    Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.

    Active Comparator: After study Control arm Good Hope

    The trial has 4 arms in a Before and After design: Arm 4. After/Good Hope area patients observed whilst receiving active comparator Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group.

    Other: Good standard care
    Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.

    Active Comparator: Before study Heartlands area

    The trial has 4 arms in a Before and After design: Arm 1. Before/Heartlands area patients observed whilst receiving active comparator Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Heartlands Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group.

    Other: Good standard care
    Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.

    Active Comparator: Before study Good Hope area

    The trial has 4 arms in a Before and After design: Arm 2. Before/Good Hope area patients observed whilst receiving active comparator Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group.

    Other: Good standard care
    Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.

    Outcome Measures

    Primary Outcome Measures

    1. Composite measure of participants not alive, need for dialysis, or progression of AKI stage [within 30 days]

      Combined endpoint

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • adult patients with an Alert for AKI issued in accordance with the national algorithm for AKI alerts (NHS England)

    • AKI stage 2 or 3 (this criterion is under review during the preparatory phase of the study)

    Exclusion Criteria:
    • patients already on dialysis for AKI at the time of alert

    • patients with End stage renal disease

    • patients <18 years of age

    • patients with no evidence of AKI on review of the automated Alert

    • patients dissenting from participation according to the Ethics application

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Heart of England hospital NHS trust Birmingham Midlands United Kingdom B9 5SS

    Sponsors and Collaborators

    • Heart of England NHS Trust
    • University of Birmingham
    • University of Warwick

    Investigators

    • Principal Investigator: Mark Thomas, FRCP, Heart of England NHS Trust

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Heart of England NHS Trust
    ClinicalTrials.gov Identifier:
    NCT02398682
    Other Study ID Numbers:
    • PB-PG-1111-26038
    First Posted:
    Mar 25, 2015
    Last Update Posted:
    Feb 26, 2018
    Last Verified:
    Feb 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by Heart of England NHS Trust
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 26, 2018